BIOMAT Database Logo BIOMAT Database Logo

Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. 2005

Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Depertment of Nephrology, Gazi University, Faculty of Medicine, Besevler-Ankara, Turkey.

Atherosclerosis is a disease of the arterial wall, with increasing wall thickness representing an early event in the progression of the disease. It has been suggested that iron overload, as assessed by increased serum ferritin concentration, may be a risk factor for atherosclerosis. The aim of this study was to investigate the relationship between the influence of intravenous (IV) iron therapy and ferritin levels and carotid intima media thickness (C-IMT) in dialysis patients. Sixty patients (51 +/- 14) years were divided into two groups according to their IMT obtained by ultrasound; group I (high risk) and group II (low risk). The parameters assessed were serum creatinine, urea, calcium, phosphorus, hemoglobin, albumin, uric acid, iron, ferritin, and lipid levels. Thirty-eight patients (88%) in group I and 5 patients (12%) in group II received IV iron therapy while 5 patients (29%) in group I and 12 patients (71%) in group II (P < 0.001) did not receive IV iron therapy. Ferritin levels were higher in group I than in group II (581 +/- 303 and 306 +/- 224) (P < 0.001). C-IMT measurements correlated with serum ferritin and with the intravenous iron dose received during the 24 months preceding the study (r = 0.315, P = 0.015; r = 0.471, P = 0.001). The findings indicate that IV iron therapy and elevated serum ferritin levels may cause an increase in the incidence of atherosclerosis.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005293 Ferritins Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types. Basic Isoferritin,Ferritin,Isoferritin,Isoferritin, Basic
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Intravenous iron therapy in end-stage renal disease.
January 2006, Seminars in dialysis,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Intravenous iron supplementation in end-stage renal disease patients.
March 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Intravenous iron and the risk of infection in end-stage renal disease patients.
January 2004, Seminars in dialysis,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Lung congestion as a risk factor in end-stage renal disease.
January 2013, Blood purification,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
End Stage Renal Disease as a Potential Risk Factor for Retinal Vein Occlusion.
November 2015, Medicine,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Smoking as a risk factor for end-stage renal failure in patients with primary renal disease.
January 2000, Contributions to nephrology,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Smoking as a risk factor for end-stage renal failure in men with primary renal disease.
September 1998, Kidney international,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
[Risk factors of atherosclerosis in end-stage renal disease patients].
January 2004, Clinical calcium,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients.
July 2002, Advances in renal replacement therapy,
Kadriye Altok Reis, and Galip Guz, and Hakan Ozdemir, and Yasemin Erten, and Veli Atalay, and Zerrin Bicik, and Zubeyde Nur Ozkurt, and Musa Bali, and Sukru Sindel
Apolipoprotein B is a risk factor for end-stage renal disease.
February 2021, Clinical kidney journal,
Copied contents to your clipboard!